ATMP | Pharmaceuticals | Regulatory Rapporteur

Skip to main content
Skip to navigation

Advanced Therapy Medicinal Products

EMA accepts new guidelines on investigational ATMPs
2025-02-17T12:54:00+00:00
Considerations in the development of allogenic and autologous cell therapies
2025-01-10T08:51:00+00:00
Small interfering RNA: regulatory challenges and therapeutic potential
2024-10-11T10:25:00+01:00
Near-term challenges of advanced therapy medicinal products: a maturing product class
2024-05-17T08:24:00+01:00
RegRapPod − May 2024
2024-05-08T16:30:00+01:00
Cell gene therapy: clinical trial application procedure of CAR-T therapy in the EU
2024-05-08T10:30:00+01:00

The first approval of a CRISPR-Cas9 gene editing medicinal product in the European Union: Casgevy
2024-05-08T10:30:00+01:00
Near-term challenges of advanced therapy medicinal products: a maturing product class
2024-05-08T10:00:00+01:00
May 2024 – Contents
2024-05-08T09:30:00+01:00
Dr Peter Marks on reflecting innovation through FDA regulation
2024-05-08T08:30:00+01:00
RegRapPod − February 2024
2024-02-20T16:51:00+00:00
RegRapPod − January 2024
2024-01-15T00:05:00+00:00

More ATMP content